152 results on '"Fiskus, W"'
Search Results
2. SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of c-MYC oncoprotein
3. BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells
4. Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer
5. HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist
6. Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells
7. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells
8. Phase I–II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo
9. Erratum: Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells
10. BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells
11. BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells
12. Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer
13. HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist
14. Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells
15. BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells
16. Abstract S3-7: Treatment with Histone Deacetylase Inhibitors Creates ‘BRCAness’ and Sensitizes Human Triple Negative Breast Cancer Cells to PARP Inhibitors and Cisplatin
17. 515 Superior Efficacy of Co-treatment with NPM1 Antagonist and FLT3 Inhibitor or Pan-histone Deacetylase Inhibitor Against Cultured and Primary Human AML Cells Co-expressing Mutant NPM1 and FLT3-ITD
18. Phase I–II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo
19. Abstract P3-04-03: Combined Epigenetic Targeting Reverses Epithelial-Mesencymal Transition (EMT) and Reduces Invasiveness of Human Breast Cancer Cells
20. 51 Deacetylation and inactivation of peroxiredoxin by SIRT2 increases sensitivity of breast cancer cells to oxidative stress
21. A novel combination therapy with histone deacetylase inhibitor and Aurora kinase inhibitor for “triple negative” breast cancers.
22. Effect of pan-histone deacetylase inhibitor panobinostat (LBH589) on CXCR4 levels and signaling and on anti-leukemia activity in combination with CXCR4 antagonists
23. Depletion of HDAC7 and de-repression of Nur77: a mechanism for sensitivity of cutaneous lymphoma (CTCL) cells to pan- histone deacetylase inhibitor Panobinostat (LBH589)
24. Novel aurora kinases-targeted combination therapy for breast cancers
25. Anti-leukemia activity of histone deacetylase (HDAC) inhibitor LBH589 involves depletion of EZH2 and DNA methyltransferase (DNMT) 1 through disruption of their chaperone association with heat shock protein (hsp) 90
26. 584 POSTER Histone deacetylase inhibitors abrogate the levels and activity of estrogen receptor (ER) α and histone deacetylase (HDAC) 6 in human breast cancer cells (BCCs)
27. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against unmutated or mutant Bcr-Abl-expressing human leukemia cells
28. Inhibition of histone deacetylase (HDAC) 6 sensitizes human leukemia and breast cancer cells to antagonists of heat shock protein (hsp) 90 and/or bortezomib (BZ)
29. Molecular mechanisms of underlying synergistic effect of combinations of histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) with docetaxel and trastuzumab against human breast cancer cells
30. Treatment with Histone Deacetylase Inhibitors Creates 'BRCAness' and Sensitizes Human Triple Negative Breast Cancer Cells to PARP Inhibitors and Cisplatin.
31. BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor.
32. Editor's Note: Superior Efficacy of a Combined Epigenetic Therapy against Human Mantle Cell Lymphoma Cells.
33. Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression.
34. Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants.
35. Retraction Notice to: Coordinated Silencing of MYC-Mediated miR-29 by HDAC3 and EZH2 as a Therapeutic Target of Histone Modification in Aggressive B-Cell Lymphomas.
36. Immune evasion phenotype is common in Richter transformation diffuse large B-cell lymphoma variant.
37. Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma.
38. Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1.
39. Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1.
40. Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1.
41. Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2.
42. Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells.
43. Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c).
44. Inhibition of GATA2 in prostate cancer by a clinically available small molecule.
45. BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma.
46. Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells.
47. EVI1 dysregulation: impact on biology and therapy of myeloid malignancies.
48. Mechanistic basis and efficacy of targeting the β-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors.
49. Editor's Note: Role of CAAT/Enhancer Binding Protein Homologous Protein in Panobinostat-mediated Potentiation of Bortezomib-induced Lethal Endoplasmic Reticulum Stress in Mantle Cell Lymphoma Cells.
50. Correction: Androgen Receptor Is the Key Transcriptional Mediator of the Tumor Suppressor SPOP in Prostate Cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.